1. From: Methoxycarbonyl-etomidate:A Novel Rapidly Metabolized and Ultra–short-acting Etomidate Analogue that Does Not Produce Prolonged Adrenocortical Suppression
Anesthes. 2009;111(2): doi: /ALN.0b013e3181ae63d1
Figure Legend:
Fig. 5. Methoxycarbonyl-etomidate (MOC-etomidate) metabolite identification. (  A  ) Mass spectrometry spectra of the major metabolite (main spectrum; m/z 289.2) and its major fragment ion (left inset spectrum; m/z 185.2). The metabolite produced a single major fragment ion at m/z with a neutral loss of m/z 104, consistent with a conserved region of the parent compound. Subsequent mass spectrometry/mass spectrometry analysis of m/z produced three major ions at m/z 94.96, , and   Right inset  shows a possible fragmentation pathway supporting the proposed metabolite structure. (  B  ) Metabolic pathway for methoxycarbonyl-etomidate upon incubation with human liver S9 fraction based on analysis of the metabolite’s major fragment ion. 
Date of download: 11/1/2017
Copyright © 2017 American Society of Anesthesiologists. All rights reserved.